Evidence map›Paper›PMID 25670241›Full record

ArticleBiopolymers2015

Functional characterization of a melittin analog containing a non-natural tryptophan analog.

Zachary Ridgway, Angela L Picciano, Pallavi M Gosavi, Yurii S Moroz, Christopher E Angevine, Amy E Chavis, Joseph E Reiner, Ivan V Korendovych, Gregory A Caputo

Open access · greenAbstract read
In one paragraph

Article in Biopolymers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Melittin kills A549 cells by targeting mitochondria and blocking mitophagy flux.Redox report : communications in free radical research · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. ACS omega · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Antimicrobial activity of a porphyrin binding peptide.Peptide science (Hoboken, N.J.) · 2018
    Article
  18. Article
  19. Article
  20. Minimalist IR and fluorescence probes of protein function.Current opinion in chemical biology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Zachary Ridgway *Department of Chemistry and Biochemistry, Rowan University, Glassboro NJ 08028.
Angela L Picciano *Department of Chemistry and Biochemistry, Rowan University, Glassboro NJ 08028.
Pallavi M GosaviDepartment of Chemistry, Syracuse University, Syracuse NY 13244.
Yurii S MorozDepartment of Chemistry, Syracuse University, Syracuse NY 13244.
Christopher E AngevineDepartment of Physics, Virginia Commonwealth University, Richmond VA 23284.
Amy E ChavisDepartment of Physics, Virginia Commonwealth University, Richmond VA 23284.
Joseph E ReinerDepartment of Physics, Virginia Commonwealth University, Richmond VA 23284.
Ivan V KorendovychDepartment of Chemistry, Syracuse University, Syracuse NY 13244.
Gregory A CaputoDepartment of Chemistry and Biochemistry, Rowan University, Glassboro NJ 08028.
Rowan University · USSyracuse University · USVirginia Commonwealth University · US

Funding

Structure-Activity Relationship in Host Defense PeptidesR15GM094330 · NIGMS · ROWAN UNIVERSITY · PI CAPUTO, GREGORY ALEXANDER · 2010 to 2010
$292k
NIGMS NIH HHS 1R15GM094330NIGMS NIH HHS R15 GM094330
6 · The paper itself

Abstract

Tryptophan (Trp) is a naturally occurring amino acid, which exhibits fluorescence emission properties that are dependent on the polarity of the local environment around the Trp side chain. However, this sensitivity also complicates interpretation of fluorescence emission data. A non-natural analogue of tryptophan, β-(1-azulenyl)-L-alanine, exhibits fluorescence insensitive to local solvent polarity and does not impact the structure or characteristics of several peptides examined. In this study, we investigated the effect of replacing Trp with β-(1-azulenyl)-L-alanine in the well-known bee-venom peptide melittin. This peptide provides a model framework for investigating the impact of replacing Trp with β-(1-azulenyl)-L-alanine in a functional peptide system that undergoes significant shifts in Trp fluorescence emission upon binding to lipid bilayers. Microbiological methods including assessment of the antimicrobial activity by minimal inhibitory concentration (MIC) assays and bacterial membrane permeability assays indicated little difference between the Trp and the β-(1-azulenyl)-L-alanine-substituted versions of melittin. Circular dichroism spectroscopy showed both that peptides adopted the expected α-helical structures when bound to phospholipid bilayers and electrophysiological analysis indicated that both created membrane disruptions leading to significant conductance increases across model membranes. Both peptides exhibited a marked protection of the respective fluorophores when bound to bilayers indicating a similar membrane-bound topology. As expected, while fluorescence quenching and CD indicate the peptides are stably bound to lipid vesicles, the peptide containing β-(1-azulenyl)-L-alanine exhibited no fluorescence emission shift upon binding while the natural Trp exhibited >10 nm shift in emission spectrum barycenter. Taken together, the β-(1-azulenyl)-L-alanine can serve as a solvent insensitive alternative to Trp that does not have significant impacts on structure or function of membrane interacting peptides.

Indexed as

FluorescenceMelittenTryptophanLipid BilayersProtein Structure, SecondaryLipid BilayersMelittenTryptophanantimicrobial peptidesazulenefluorescencetryptophan analogs

Identifiers

PMID25670241
PMCPMC4516667
OpenAlexW2154386481

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.